Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Attention Deficit Hyperactivity Disorder Clear all
Completed No phase listed Observational

Pediatric Bipolar Disorder Study at UCLA

NCT00961935
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 5, 2026, 4:06 AM EDT
Recruiting Phase 4 Interventional

Medication Treatment of ADHD in Pediatric Epilepsy

NCT07594652
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate hydrochloride (Jornay PM)
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

NCT04398225
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 5, 2026, 4:06 AM EDT
Completed No phase listed Observational Results available

The Parenting Young Children Check-up: Proof-of-Concept Trial

NCT04113304
View directory record Official record
Conditions
Disruptive Behavior Disorders
Interventions
Parenting Young Children Check-up (PYCC)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 5, 2026, 4:06 AM EDT
Enrolling by invitation No phase listed Observational

Pediatric Behavioral Health Integrated Care: Indiana Statewide Strategic Plan to Address the Growing Mental Health Crisis

NCT07216638
View directory record Official record
Conditions
Implementation Research, Depressive Disorder, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Conduct Disorders in Children, Pediatric Mental Health Services
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
5 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Comparative Effectiveness of Primary Care-based Interventions for Pediatric ADHD

NCT02105142
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
ADHD Group Visits, ADHD Group Visits plus Online Discussion Portal, Computer Decision Support
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 12 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 8, 2015 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT00318448
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Zolpidem (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

NCT01907360
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
HLD200 (methylphenidate hydrochloride)
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Sep 5, 2026, 4:06 AM EDT
Active, not recruiting Not applicable Interventional

tRNS Treatment for ADHD Symptoms

NCT06189703
View directory record Official record
Conditions
ADHD
Interventions
tRNS
Device
Lead sponsor
Innosphere
Industry
Eligibility
7 Years to 12 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Not applicable Interventional Results available

Software Treatment for Actively Reducing Severity of ADHD

NCT02674633
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
AKL-T01, AKL-T09
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Dothan, Alabama • Scottsdale, Arizona • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 5, 2026, 4:06 AM EDT
Recruiting Not applicable Interventional

Impact of Parental Emotion Regulation on the Treatment of ADHD

NCT05299814
View directory record Official record
Conditions
ADHD
Interventions
Behavioral Parenting Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years to 12 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 2Phase 3 Interventional

Dasotraline Pediatric ADHD Study

NCT02428088
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline, Placebo Comparator
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Dothan, Alabama • National City, California • Paramount, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 5, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

NCT02736656
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
16
States / cities
Little Rock, Arkansas • Long Beach, California • Colorado Springs, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Results available

Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

NCT01986062
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
AR11, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 5, 2026, 4:06 AM EDT
Not yet recruiting No phase listed Observational

Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy

NCT07640802
View directory record Official record
Conditions
Irritability, Disruptive Mood Dysregulation Disorder, Oppositional Defiant Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Psychotherapy
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

NCT00485875
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

NCT04786730
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Little Rock, Arkansas • Decatur, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT00500149
View directory record Official record
Conditions
ADHD
Interventions
Vyvanse (lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
9
States / cities
Little Rock, Arkansas • Irvine, California • Wildomar, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

NCT02618434
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810 (18 mg), SPN-810 (36 mg), Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
32
States / cities
Chandler, Arizona • Little Rock, Arkansas • Imperial, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Results available

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

NCT00434213
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daytrana
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Scottsdale, Arizona • Irvine, California • San Marcos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 5, 2026, 4:06 AM EDT
Terminated Phase 4 Interventional Results available

Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention

NCT03279952
View directory record Official record
Conditions
ADHD
Interventions
CNS Stimulant
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years to 12 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 5, 2026, 4:06 AM EDT
Not yet recruiting Not applicable Interventional

Pediatric Epilepsy

NCT07350551
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB series response pad; Adtech Behnke-Fried micro-electrodes; Neuralynx or Blackrock electrophysiology system; Blackrock Cerestim or Natus Nicolet stimulator
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 5, 2026, 4:06 AM EDT
Completed Not applicable Interventional Results available

PK/PD Pediatric ADHD Classroom Study

NCT02536105
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 5, 2026, 4:06 AM EDT